Fig. 3
From: PCR-based zebrafish model for personalised medicine in head and neck cancer
Dose-dependent response of the tumour xenograft to cisplatin treatment evaluated using quantitative PCR. Human larynx carcinoma UT-SCC-42A tumour xenograft in zebrafish larvae was subjected to different concentrations of cisplatin (0–3 µg/ml). The tumour response was evaluated using a quantitative PCR method. Each group had 20 fish, with 10 fish pooled together